ATIVAN Solution for injection (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Ativan 4mg/ml Solution for injection.
Qualitative and quantitative composition
Lorazepam 4 mg/ml. Lorazepam (INN, BAN) is chemically defined as 7-chloro-5-(o-chlorphenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one. Excipient(s) with known effect: Ativan Injection contains 20.9mg/ml ...
Pharmaceutical form
Solution for injection. Clear, colourless solution supplied in clear glass ampoules.
Therapeutic indications
Pre-operative medication or premedication for uncomfortable or prolonged investigations, e.g. bronchoscopy, arteriography, endoscopy. The treatment of acute anxiety states, acute excitement or acute mania. ...
Posology and method of administration
Posology Dosage and duration of therapy should be individualised. The lowest effective dose should be prescribed for the shortest time possible. Treatment in all patients should be withdrawn gradually ...
Contraindications
Acute pulmonary insufficiency Hypersensitivity to benzodiazepines, including lorazepam or to any of the excipients listed in section 6.1. Sleep apnoea syndrome. Myasthenia gravis. Severe hepatic insufficiency. ...
Special warnings and precautions for use
Prior to use, Ativan Injection may be diluted for IM administration and should always be diluted for IV administration with equal amounts of compatible diluent (see section 4.2). Intravenous injection ...
Interaction with other medicinal products and other forms of interaction
Not recommended: Concomitant intake with alcohol The sedative effects may be enhanced when the product is used in combination with alcohol. This affects the ability to drive or use machines. The benzodiazepines, ...
Pregnancy and lactation
Pregnancy Ativan Injection should not be used during pregnancy, especially during the first and last trimesters, unless in the judgement of the physician such administration is clinically justifiable. ...
Effects on ability to drive and use machines
This medicine can impair cognitive function and can affect a patients ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. ...
Undesirable effects
Blood and lymphatic system disorders Frequency not known: Thrombocytopenia, agranulocytosis, pancytopenia Immune system disorders Frequency not known: Hypersensitivity reactions, anaphylactic/oid reactions ...
Overdose
In the management of overdosage with any drug, it should be borne in mind that multiple agents may have been taken. Overdosage of benzodiazepines is usually manifested by degrees of central nervous system ...
Pharmacodynamic properties
Pharmacotherapeutic group: Benzodiazepine derivatives ATC code: N05BA06 Ativan is a benzodiazepine with anxiolytic, sedative, hypnotic, anticonvulsant and muscle relaxant properties.
Pharmacokinetic properties
Absorption Ativan Injection is readily absorbed when given intramuscularly. Peak plasma concentrations occur approximately 60-90 minutes following intramuscular administration. Metabolism Ativan is metabolised ...
Preclinical safety data
Lorazepam glucuronide, the major metabolite of lorazepam, has no demonstrable CNS activity in animals. Carcinogenicity No evidence of carcinogenic potential emerged in rats and mice during an 18-month ...
List of excipients
Polyethylene glycol 400 Benzyl alcohol Propylene glycol
Incompatibilities
Not applicable.
Shelf life
1 year.
Special precautions for storage
Store and transport refrigerated (2°C to 8°C). Keep ampoule in the outer carton to protect from light.
Nature and contents of container
1ml solution in 2ml ampoules (Type I glass) with a one-point-cut opening, position marked by red spot in pack sizes of 10. Not all pack sizes may be marketed.
Special precautions for disposal and other handling
No special requirements for disposal. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Marketing authorization holder
Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
Marketing authorization number(s)
PL 00057/1279
Date of first authorization / renewal of the authorization
Date of latest renewal: 12 March 2009
Date of revision of the text
02/2019
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
